Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma

Melanoma Research

Volumn 24, Issue 5, 2014, Pages 468-474

  Lee, Clara I ^a,d   Menzies, Alexander M ^c,d   Haydu, Lauren E ^c,d   Azer, Mary ^a   Clements, Arthur ^a,d   Kefford, Richard F ^a,b,c,d   Long, Georgina V ^b,c,d  

^a WESTMEAD HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

BRAF inhibitor; Dabrafenib; Fever; Management; MEK inhibitor; Melanoma; Prophylaxis; Pyrexia; Toxicity; Trametinib

Indexed keywords

CORTICOSTEROID; DABRAFENIB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE; TRAMETINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; FEMALE; HUMAN; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEVER; MELANOMA; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RETROSPECTIVE STUDY; TEMPERATURE; TREATMENT OUTCOME;

ACETAMINOPHEN; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FEVER; HUMANS; IMIDAZOLES; MALE; MELANOMA; MIDDLE AGED; OXIMES; PYRIDONES; PYRIMIDINONES; RETROSPECTIVE STUDIES; TEMPERATURE; TREATMENT OUTCOME;

EID: 84926097366     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000110     Document Type: Article

References (17)

1. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-1246.
2. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118:4014-4023.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
4. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
5. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAFmutated melanoma. N Engl J Med 2012;367:107-114.
6. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
7. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
9. Flaherty KT, Infante JR, Falchook GS, Weber J, Daud A, Hamid O, et al. Phase I/II expansion cohort of BRAF inhibitor GSK2118436 +MEK inhibitor GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor. Pigment Cell Melanoma Res 2011;24:1022 (abstract LBA1021-1024).
10. Ouellet D, Grossmann KF, Limentani G, Nebot N, Lan K, Knowles L, et al. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. J Pharm Sci 2013;102:3100-3109.
11. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
12. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-1901.
13. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013;494:251-255.
14. Schuchter LM, Kudchadkar RR, Gonzalez R, Lawrence DP, Sosman JA, Infante JR, et al. Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM) [abstract]. J Clin Oncol 2013;31:9066.
15. Dummer R, Robert C, Nyakas M, McArthur GA, Kudchadkar RR, Gomez-Roca C, et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma [abstract]. J Clin Oncol 2013;31:9028.
16. Gonzalez R, Ribas A, Daud A, Pavlick A, Gajewski TF, Puzanov I, et al. Phase 1B study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7). Ann Oncol 2012;23:ixe19 (abstract LBA28-PR).
17. Kefford R, Miller WH, DS-W Tan, Sullivan RJ, Long G, Dienstmann R, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors [abstract]. J Clin Oncol 2013;31:9029.